Sugi Predict

Sugi Predict / Compounds / SCHEMBL12458255

SCHEMBL12458255

SCHEMBL12458255

CCOC(=O)c1cn(C(C)C)cn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.49
▸ CYP1A2 P05177 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ KDM5A P29375 6/20 0.42
▸ GAA P10253 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ GABRA2 P47869 2/20 0.40
▸ GABRB2 P47870 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GABRP O00591 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA4 P48169 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25588351 0.89 KDM5A (0.41) NOTUMALDH1A1KDM5AGABRA2GABRB2
SCHEMBL29215889 0.88 NOTUM (0.47) NOTUMCYP1A2KDM4EALDH1A1HPGD
SCHEMBL17750114 0.88 NOTUM (0.47) NOTUMCYP1A2KDM4EALDH1A1HPGD
SCHEMBL15148680 0.88 NOTUM (0.47) NOTUMCYP1A2KDM4EALDH1A1HPGD
SCHEMBL28934505 0.88 NOTUM (0.47) NOTUMCYP1A2KDM4EALDH1A1HPGD
SCHEMBL29215881 0.88 NOTUM (0.47) NOTUMCYP1A2KDM4EALDH1A1HPGD
SCHEMBL15148626 0.88 NOTUM (0.47) NOTUMCYP1A2KDM4EALDH1A1HPGD
SCHEMBL28934504 0.88 NOTUM (0.47) NOTUMCYP1A2KDM4EALDH1A1HPGD
SCHEMBL21026472 0.88 NOTUM (0.47) NOTUMCYP1A2KDM4EALDH1A1HPGD
SCHEMBL29215901 0.86 NOTUM (0.46) NOTUMCYP1A2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 — — EP disclosed
WO-2025002177-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2025-01-02 — — WO disclosed
WO-2024097948-A1 DEGRADERS OF MDM2 AND USES THEREOF ROIVANT DISCOVERY, INC. (US) 2024-05-10 — — WO disclosed
EP-3870581-B1 TRICYCLIC PESTICIDAL COMPOUNDS BASF SE (DE) 2023-06-14 — — EP disclosed
CN-112041320-B Compound capable of being used as tumor inhibitor and preparation method and application thereof 甘李药业股份有限公司 2023-05-23 — — CN disclosed
US-11639355-B2 Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2023-05-02 — — US disclosed
US-11339171-B2 MDM2 inhibitors GAN & LEE PHARMACEUTICALS (CN) 2022-05-24 — — US disclosed
US-11339171-B2 MDM2 inhibitors GAN & LEE PHARMACEUTICALS (CN) 2022-05-24 — — US disclosed
US-20210230164-A1 IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2021-07-29 — — US disclosed
US-20210079007-A1 MDM2 Inhibitors GAN & LEE PHARMACEUTICALS (CN) 2021-03-18 — — US disclosed
US-20130281430-A1 Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-24 — — US disclosed
US-20130281430-A1 Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-24 — — US disclosed
WO-2013111105-A1 IMIDAZOPYRROLIDINONE COMPOUNDS NOVARTIS AG (CH) 2013-08-01 — — WO disclosed
WO-2013111105-A1 IMIDAZOPYRROLIDINONE COMPOUNDS NOVARTIS AG (CH) 2013-08-01 — — WO disclosed
EP-2537831-A1 IMIDAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-26 — — EP disclosed
EP-2537831-A1 IMIDAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-26 — — EP disclosed
US-20120316170-A1 Imidazole Derivative DAIICHI SANKYO COMPANY LIMITED (JP) 2012-12-13 — — US disclosed
US-20120316170-A1 Imidazole Derivative DAIICHI SANKYO COMPANY LIMITED (JP) 2012-12-13 — — US disclosed
US-20120316170-A1 Imidazole Derivative DAIICHI SANKYO COMPANY LIMITED (JP) 2012-12-13 — — US disclosed
WO-2011102404-A1 IMIDAZOLE DERIVATIVE 第一三共株式会社 (JP) 2011-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230164-A1 IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF TP53, MDM2, TP53BP1 NOTUM 4225/4885CYP1A2 518/4885KDM4E 4629/4885
US-11639355-B2 Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors TP53, MDM2, TP53BP1 NOTUM 4022/4885CYP1A2 992/4885KDM4E 4033/4885
US-20130281430-A1 Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments INMT, IDO1, CHRM1 NOTUM 1723/4885CYP1A2 349/4885KDM4E 3274/4885
US-11339171-B2 MDM2 inhibitors MDM2, MDM4, TP53 NOTUM 666/4885CYP1A2 2585/4885KDM4E 2527/4885
US-20210079007-A1 MDM2 Inhibitors MDM2, MDM4, TP53 NOTUM 666/4885CYP1A2 2585/4885KDM4E 2527/4885
US-20120316170-A1 Imidazole Derivative S1PR2, S1PR1, SPHK2 NOTUM 368/4885CYP1A2 1239/4885KDM4E 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.